This newsletter presents you the following key sessions:
1. Adjuvant osimertinib significantly prolongs the overall survival of patients with EGFR-mutant, early-stage
non-small cell lung cancer
2. Vorasidenib delays disease progression or death in grade 2 glioma with IDH1/2 mutation
3. Atezolizumab plus cabozantinib not superior to cabozantinib alone after progression on prior immune
checkpoint inhibitor treatment in metastatic renal cell carcinoma
4. Durvalumab plus chemotherapy and bevacizumab, followed by maintenance durvalumab, bevacizumab
and olaparib, in newly diagnosed advanced ovarian cancer patients
5. The phase III SONIA trial challenges the universal need for CDK4/6 inhibition in the first-line treatment
of patients with hormone-receptor positive advanced breast cancer
![BMS Opdivo leaderboard banner BJMO ASCO enewsletter 12 14 16 en 27 juni 2023](/images/ASCO2023/BMS_Opdivo_leaderboard_banner_BJMO_ASCO_enewsletter_12_14_16_en_27_juni_2023.jpg)
![Eli Lilly Verzenios halfway banner BJMO ASCO 12 juni 2023](/images/ASCO2023/Eli_Lilly_Verzenios_halfway_banner_BJMO_ASCO_12_juni_2023.jpg)
![MSD Keytruda Pan Tumour footer Banner BJMO ASCO 12 juni 2023](/images/ASCO2023/MSD_Keytruda_Pan_Tumour_footer_Banner_BJMO_ASCO_12_juni_2023.gif)